{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:02:18Z","timestamp":1793700138831,"version":"4.5.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC. The dual primary endpoint of progression-free survival is event driven; data were not mature at data cutoff. BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403\u20134.253; 99.8% CI: 1.019\u20135.855; one-sided\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0008). Median duration of response was 13.9 versus 11.1 months. At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318\u20130.691; repeated CI: 0.166\u20131.322). Serious adverse event rates were 37.7% versus 34.6%. The safety profiles were consistent with those known for each agent. BREAKWATER demonstrated a significantly improved response rate that was durable for first-line EC+mFOLFOX6 versus SOC in patients with BRAF V600E mCRC. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04607421\" ext-link-type=\"uri\">NCT04607421<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-024-03443-3","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T15:02:53Z","timestamp":1737817373000},"page":"901-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"Scott","family":"Kopetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-0612","authenticated-orcid":false,"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-1997","authenticated-orcid":false,"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-2030","authenticated-orcid":false,"given":"Harpreet Singh","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-9344","authenticated-orcid":false,"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4661-5540","authenticated-orcid":false,"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5454","authenticated-orcid":false,"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-5065","authenticated-orcid":false,"given":"Timothy S.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-9432","authenticated-orcid":false,"given":"Elena","family":"Beyzarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9923-9985","authenticated-orcid":false,"given":"Xiaoxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1760-4697","authenticated-orcid":false,"given":"Graham","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2415-5355","authenticated-orcid":false,"given":"Xiaosong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"3443_CR1","first-page":"1","volume":"42","author":"J Tabernero","year":"2022","unstructured":"Tabernero, J. et al. The evolving treatment landscape in BRAF-V600E\u2013mutated metastatic colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u201310 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3443_CR2","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran, B. et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117, 4623\u20134632 (2011).","journal-title":"Cancer"},{"key":"3443_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 19, 603\u2013615 (2018).","journal-title":"Lancet Oncol."},{"key":"3443_CR4","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.23.00774","volume":"41","author":"GJ Riely","year":"2023","unstructured":"Riely, G. J. et al. Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non\u2013small-cell lung cancer. J. Clin. Oncol. 41, 3700\u20133711 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR5","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","volume":"23","author":"JP Delord","year":"2017","unstructured":"Delord, J. P. et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin. Cancer Res. 23, 5339\u20135348 (2017).","journal-title":"Clin. Cancer Res."},{"key":"3443_CR6","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1158\/1538-7445.AM2012-3790","volume":"72","author":"DD Stuart","year":"2012","unstructured":"Stuart, D. D. et al. Abstract 3790: preclinical profile of LGX818: a potent and selective RAF kinase inhibitor. Cancer Res. 72, 3790 (2012).","journal-title":"Cancer Res."},{"key":"3443_CR7","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","volume":"33","author":"RB Corcoran","year":"2015","unstructured":"Corcoran, R. B. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. 33, 4023\u20134031 (2015).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100\u2013103 (2012).","journal-title":"Nature"},{"key":"3443_CR9","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer. N. Engl. J. Med. 381, 1632\u20131643 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3443_CR10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726\u2013736 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3443_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris, V. K. et al. Treatment of metastatic colorectal cancer: ASCO Guideline. J. Clin. Oncol. 41, 678\u2013700 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jnci\/djab042","volume":"113","author":"R Cohen","year":"2021","unstructured":"Cohen, R. et al. BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. J. Natl. Cancer Inst. 113, 1386\u20131395 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"3443_CR13","first-page":"217","volume":"10","author":"YN Han","year":"2022","unstructured":"Han, Y. N. et al. Tolerability on serious adverse events of first-line bevacizumab and cetuximab for RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Healthc. (Basel) 10, 217 (2022).","journal-title":"Healthc. (Basel)"},{"key":"3443_CR14","doi-asserted-by":"publisher","first-page":"Abstract 119","DOI":"10.1200\/JCO.2023.41.4_suppl.119","volume":"41","author":"S Kopetz","year":"2023","unstructured":"Kopetz, S. et al. BREAKWATER safety lead-in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). J. Clin. Oncol. 41, Abstract 119 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR15","doi-asserted-by":"crossref","unstructured":"Jennison, C., Turnbull, B. W. Group Sequential Methods with Applications to Clinical Trials (Chapman and Hall\/CRC, 1999).","DOI":"10.1201\/9781584888581"},{"key":"3443_CR16","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011\u20132019 (2011).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR17","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","volume":"30","author":"KM Tveit","year":"2012","unstructured":"Tveit, K. M. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 30, 1755\u20131762 (2012).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","volume":"377","author":"TS Maughan","year":"2011","unstructured":"Maughan, T. S. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377, 2103\u20132114 (2011).","journal-title":"Lancet"},{"key":"3443_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa0808268","volume":"360","author":"J Tol","year":"2009","unstructured":"Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563\u2013572 (2009).","journal-title":"N. Engl. J. Med."},{"key":"3443_CR20","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.22.01420","volume":"41","author":"S Stintzing","year":"2023","unstructured":"Stintzing, S. et al. FOLFOXIRI plus cetuximab or bevacizumab as first-line treatment of BRAFV600E-mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study. J. Clin. Oncol. 41, 4143\u20134153 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR21","doi-asserted-by":"publisher","first-page":"Abstract 535P","DOI":"10.1093\/annonc\/mdu333.38","volume":"25","author":"CA Gomez-Roca","year":"2014","unstructured":"Gomez-Roca, C. A. Encorafenib (LGX818), an oral BRAF inhibitor, in patients (Pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion in an open-label, phase 1 study. Ann. Oncol. 25, Abstract 535P (2014).","journal-title":"Ann. Oncol."},{"key":"3443_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 8, 428\u2013443 (2018).","journal-title":"Cancer Discov."},{"key":"3443_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.20.01994","volume":"39","author":"S Kopetz","year":"2021","unstructured":"Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-Mutant metastatic colorectal cancer (SWOG S1406). J. Clin. Oncol. 39, 285\u2013294 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.22.01423","volume":"41","author":"CM Parseghian","year":"2023","unstructured":"Parseghian, C. M. et al. Resistance mechanisms to anti-epidermal growth factor receptor therapy in RAS\/RAF wild-type colorectal cancer vary by regimen and line of therapy. J. Clin. Oncol. 41, 460\u2013471 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR25","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1158\/1078-0432.CCR-22-3894","volume":"29","author":"S Napolitano","year":"2023","unstructured":"Napolitano, S. et al. Antitumor efficacy of dual blockade with encorafenib + cetuximab in combination with chemotherapy in human BRAFV600E-mutant colorectal cancer. Clin. Cancer Res. 29, 2299\u20132309 (2023).","journal-title":"Clin. Cancer Res."},{"key":"3443_CR26","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","volume":"30","author":"S Kopetz","year":"2024","unstructured":"Kopetz, S. et al. Molecular profiling of BRAF V600E\u2013mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Nat. Med. 30, 3261\u20133271 (2024).","journal-title":"Nat. Med."},{"key":"3443_CR27","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.22.01693","volume":"41","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem, E. et al. ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAF(V600E)-mutant metastatic colorectal cancer. J. Clin. Oncol. 41, 2628\u20132637 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3443_CR28","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3443_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/fon-2022-1249","volume":"20","author":"E Elez","year":"2024","unstructured":"Elez, E. et al. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC. Future Oncol. 20, 653\u2013663 (2024).","journal-title":"Future Oncol."},{"key":"3443_CR30","doi-asserted-by":"publisher","first-page":"S428","DOI":"10.1016\/j.annonc.2024.08.584","volume":"35","author":"J Tabernero","year":"2024","unstructured":"Tabernero, J. et al. Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI). Ann. Oncol. 35, S428\u2013S481 (2024).","journal-title":"Ann. Oncol."},{"key":"3443_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"3443_CR32","unstructured":"Welcome to the ICH MedDRA website. Medical Dictionary for Regulatory Activities (MedDRA). https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english\/welcome"},{"key":"3443_CR33","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2009)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03443-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:26:06Z","timestamp":1742372766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03443-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3443"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03443-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. has stock and other ownership interests in Lylon, Lutris, MolecularMatch and Navire; a consulting or advisory role at AbbVie, Amal Therapeutics, AstraZeneca\/MedImmune, Bayer Health, Bicara Therapeutics, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Endeavor BioMedicines, Flame Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Healthcare, Inivata, Ipsen, Iylon, Jacobio, Jazz Pharmaceuticals, Lilly, Lutris, Merck, Mirati Therapeutics, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapeutics, Servier and Xilis and received research funding from Amgen, Array BioPharma, Biocartis, Daiichi Sankyo, EMD Serono, Genentech\/Roche, Guardant Health, Lilly, MedImmune, Novartis and Sanofi. T.Y. receives honoraria from Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo and Takeda and research funding from Amgen, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia, Molecular Health, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer, Roche Diagnostics, Sanofi, Sumitomo Dainippon, Sysmex and Taiho Pharmaceutical. E.V.C. has a consulting or advisory role at AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical and Terumo. C.E. has a consulting role at Bayer, Boston Scientific, GlaxoSmithKline, HalioDx, Merck, Mirati, Hookipa, J&J, Natera, Roche, Seagen, Taiho and Veloxis and receives research funding (to VUMC) from Elevar, Hutchinson, Merck and Pfizer. T.W.K. receives research funding (institutional) from AstraZeneca, Sanofi and Roche\/Genentech. H.S.W. has a consulting or advisory role at Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapeutics, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche\/Genentech, Seagen, Servier, Shire, Sirtex Medical, Takeda (Hutchinson Med) and Zymeworks and recieves research funding (institutional) from Merck KGaA, MSD, Pfizer and Sirtex Medical. J.D. has a consulting or advisory role at Amgen, Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA and Pierre Fabre and receives research funding from AstraZeneca\/MedImmune, BeiGene, Bionomics, Bristol Myers Squibb, GSK, Lilly, Novartis and Roche. F.C. has a consulting or advisory role at Amgen, Bayer, Merck KGaA, Pfizer and Roche\/Genentech and receives research funding from Amgen, Bayer, Bristol Myers Squibb, Ipsen, Merck KGaA, MSD, Roche\/Genentech, Servier and Symphogen. R.Y. has a consulting or advisory role at Array BioPharma\/Pfizer, Mirati Therapeutics, Zai Lab and Amgen and receives research funding from Array BioPharma, Boehringer Ingelheim, Mirati Therapeutics, Pfizer and Daiichi Sankyo. T.S.M. has a consulting or advisory role at AstraZeneca, Pierre Fabre and Vertex; receives research funding (institutional) from Almac Diagnostics, AstraZeneca, Merck KgAA and PsiOxus Therapeutics; and has a patent pending. E.B., Xiaoxi Zhang and G.F. are employees of and have stock and other ownership interests in Pfizer. Xiaosong Zhang is an employee of and has stock and other ownership interests in Pfizer and has patents, royalties or other intellectual property via Johns Hopkins University. J.T. has a consulting or advisory role at Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna, IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapeutics, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seagen, Servier, Taiho Pharmaceutical, Tessa Therapeutics and TheraMyc and has other relationships with Amgen, Array Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Research UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaci\u00f3n Cient\u00edfica de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer, Genentech, HalioDx, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapeutics, PeerView Institute for Medical Education, Pfizer, PharmaMar, Physicans\u2019 Education Resource, Sanofi-Aventis, Servier and Taiho Pharmaceutical.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}